{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T09:07:57Z","timestamp":1723194477610},"reference-count":49,"publisher":"Akademiai Kiado Zrt.","issue":"8","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,2,20]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> A m\u00e1jtranszplant\u00e1ci\u00f3s program r\u00e9szek\u00e9nt 1995 \u00f3ta\n                    l\u00e9tezik folyamatosan vezetett v\u00e1r\u00f3lista Magyarorsz\u00e1gon.\n                        <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> A legfontosabb v\u00e1r\u00f3lista-param\u00e9terek\n                    meg\u00e1llap\u00edt\u00e1sa \u00e9s nemzetk\u00f6zi \u00f6sszehasonl\u00edt\u00e1sa. <jats:italic>M\u00f3dszer:<\/jats:italic> A\n                    szerz\u0151k az 1995. janu\u00e1r 1. \u00e9s 2019. december 31. k\u00f6z\u00f6tt els\u0151 m\u00e1j\u00e1t\u00fcltet\u00e9s\n                    c\u00e9lj\u00e1b\u00f3l v\u00e1r\u00f3list\u00e1ra helyezett betegek adatait elemezt\u00e9k.\n                        <jats:italic>Eredm\u00e9nyek:<\/jats:italic> \u00d6sszesen 1722 beteget helyeztek v\u00e1r\u00f3list\u00e1ra,\n                    1608 feln\u0151ttet, 114 gyermeket. A f\u00e9rfiak ar\u00e1nya 51,2%, az \u00e1tlag\u00e9letkor 45,6 \u00e9v.\n                    Az \u00e9vente regisztr\u00e1lt \u00faj jel\u00f6ltek sz\u00e1ma 25 \u00e9v sor\u00e1n k\u00f6zel az \u00f6tsz\u00f6r\u00f6s\u00e9re\n                    emelkedett. A list\u00e1ra helyez\u00e9s leggyakoribb indik\u00e1ci\u00f3ja a v\u00edruseredet\u0171 cirrhosis\n                    volt (n = 451). Ezt k\u00f6vette a cholestaticus (n = 314) \u00e9s az alkoholos\n                    m\u00e1jbetegs\u00e9g (n = 264). Rosszindulat\u00fa daganat, 82%-ban hepatocellularis carcinoma\n                    miatt 215 beteget regisztr\u00e1ltak. Kr\u00f3nikus betegs\u00e9gekben az \u00e1tlagos Model for\n                    End-Stage Liver Disease pontsz\u00e1m a regisztr\u00e1l\u00e1skor 13,5 volt. A 2018. december\n                    31-ig list\u00e1ra helyezettek (n = 1618) 61%-a r\u00e9szes\u00fclt m\u00e1j\u00e1t\u00fcltet\u00e9sben, 24%-a\n                    v\u00e1rakoz\u00e1s k\u00f6zben meghalt, 7%-a a m\u0171t\u00e9tre alkalmatlann\u00e1 v\u00e1lt. A m\u0171t\u00e9t el\u0151tti\n                    medi\u00e1n v\u00e1rakoz\u00e1si id\u0151 248 nap volt a kr\u00f3nikus \u00e9s 2 nap az akut betegek list\u00e1j\u00e1n.\n                    A transzplant\u00e1lt tumoros betegek (n = 132) szignifik\u00e1nsan r\u00f6videbb ideig v\u00e1rtak\n                    m\u0171t\u00e9tre (medi\u00e1n 115,5 nap), mint a t\u00f6bbi kr\u00f3nikus beteg (n = 803, medi\u00e1n 282\n                    nap). Az Eurotransplanthoz val\u00f3 csatlakoz\u00e1s ut\u00e1ni id\u0151szakban (2013. j\u00falius 1. \u00e9s\n                    2018. december 31. k\u00f6z\u00f6tt) a transzplant\u00e1ci\u00f3s ar\u00e1ny n\u00f6vekedett (67%), a\n                    v\u00e1r\u00f3lista-hal\u00e1loz\u00e1s (meghaltak + m\u0171t\u00e9tre alkalmatlann\u00e1 v\u00e1ltak) 24%-ra cs\u00f6kkent.\n                        <jats:italic>Megbesz\u00e9l\u00e9s:<\/jats:italic> A v\u00e1r\u00f3lista folyamatos b\u0151v\u00fcl\u00e9se hozz\u00e1j\u00e1rult a\n                    hazai m\u00e1j\u00e1t\u00fcltet\u00e9si program fejl\u0151d\u00e9s\u00e9hez. A hazai v\u00e1r\u00f3lista diagn\u00f3zis szerinti\n                    \u00f6sszet\u00e9tele a m\u00e1sok \u00e1ltal k\u00f6z\u00f6ltekkel nagyr\u00e9szt egyezik. A transzplant\u00e1ltak\n                    ar\u00e1nya a nemzetk\u00f6zi \u00e1tlagnak megfelel\u0151. A v\u00e1r\u00f3lista-hal\u00e1loz\u00e1s \u00e9s a m\u0171t\u00e9t el\u0151tti\n                    v\u00e1rakoz\u00e1si id\u0151 a magyarorsz\u00e1gin\u00e1l alacsonyabb don\u00e1ci\u00f3s aktivit\u00e1s\u00fa vagy\n                    jelent\u0151sen nagyobb v\u00e1r\u00f3list\u00e1val rendelkez\u0151 orsz\u00e1gok\u00e9hoz hasonl\u00f3.\n                        <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> V\u00e1r\u00f3lista-param\u00e9tereink jav\u00edt\u00e1s\u00e1hoz a\n                    transzplant\u00e1ci\u00f3k sz\u00e1m\u00e1nak tov\u00e1bbi n\u00f6vel\u00e9se sz\u00fcks\u00e9ges. Orv Hetil. 2022; 163(8):\n                    301\u2013311.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> The Hungarian liver transplant program including\n                    waiting list started in 1995. <jats:italic>Objective:<\/jats:italic> Evaluation of the\n                    wait-list parameters and comparing them with those in the literature.\n                        <jats:italic>Method:<\/jats:italic> Data of patients listed for primary liver\n                    transplantation between 1995 and 2019 were analyzed. <jats:italic>Results:<\/jats:italic> A\n                    total of 1722 recipient candidates were registered on the liver transplant\n                    waiting list: 1608 adults (51.2% men) with mean age of 45.6 year and 114\n                    patients aged &lt;18 year. Virus-induced cirrhosis was the leading indication of\n                    listing (n = 451) and cholestatic liver diseases (n = 314) and alcoholic\n                    cirrhosis (n = 264) thereafter. The mean Model for End-Stage Liver Disease score\n                    was 13.5 for those with chronic disease. 61% of 1618 patients listed before\n                    December 31, 2018 underwent liver transplantation and 31% were removed from the\n                    wait-list for death or clinical deterioration. After joining Eurotransplant\n                    (period of 01. 07. 2013\u201331. 12. 2018), the transplant rate was 67%, the waiting\n                    list removal due to death\/too sick for operation decreased to 24%. The median\n                    waiting time till transplantation was 248 days for those on elective and 2 days\n                    on acute list. Patients grafted with malignancy (n = 132) waited significantly\n                    shorter time than those with chronic non-malignant liver disease (median 115.5\n                        <jats:italic>versus<\/jats:italic> 282 days). <jats:italic>Discussion:<\/jats:italic> The\n                    composition of our waiting list by primary liver disease was similar to that of\n                    countries with large burden of hepatitis C. Transplant rate was average,\n                    wait-list mortality and waiting time were in line with those observed in\n                    low-donation countries or in the case of large volume waiting list.\n                        <jats:italic>Conclusion:<\/jats:italic> Listing of increasing the number of patients\n                    contributed to evolution of our liver transplant program. To improve our\n                    parameters, increasing transplant activity is warranted. Orv Hetil. 2022;\n                    163(8): 301\u2013311.<\/jats:p>","DOI":"10.1556\/650.2022.32356","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T21:00:51Z","timestamp":1668805251000},"page":"301-311","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["M\u00e1jv\u00e1r\u00f3lista 1995\u20132019: a hazai adatok nemzetk\u00f6zi \u00f6sszehasonl\u00edt\u00e1sa"],"prefix":"10.1556","volume":"163","author":[{"given":"D\u00e9nes","family":"G\u00f6r\u00f6g","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Gerlei","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Schuller","sequence":"additional","affiliation":[{"name":"Uzsoki Utcai K\u00f3rh\u00e1z, Hepatol\u00f3giai Ambulancia Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antal","family":"Dezs\u0151fi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, I. Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Piros","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Sandil","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Feh\u00e9rv\u00e1ri","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Fazakas","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Doros","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"K\u00f3bori","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Transzplant\u00e1ci\u00f3s \u00e9s Seb\u00e9szeti Klinika Budapest, Baross u. 23\u201325., 1082 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.3748\/wjg.v20.i18.5363","article-title":"Liver transplantation: fifty years of experience","volume":"20","author":"1 Song","year":"2014","unstructured":"1 Song AT, Avelino-Silva VI, Pecora RA, et al. Liver transplantation: fifty years of experience. World J Gastroenterol. 2014; 20: 5363-5374.","journal-title":"World J Gastroenterol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ctr.12499","article-title":"Geographic inequity results in disparate mortality: a multivariate intent-to-treat analysis of liver transplant data","volume":"29","author":"2 Rana","year":"2015","unstructured":"2 Rana A, Riaz IB, Gruessner AC, et al. Geographic inequity results in disparate mortality: a multivariate intent-to-treat analysis of liver transplant data. Clin Transplant. 2015; 29: 484-491.","journal-title":"Clin Transplant"},{"key":"ref2","unstructured":"3 Perner F, Petr\u00e1nyi Gy. (eds.) Organ transplantation. [Szerv\u00e1t\u00fcltet\u00e9s.] Medicina K\u00f6nyvkiad\u00f3, Budapest, 2013. [Hungarian]"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00508-016-1046-1","article-title":"Recommendations of the Austrian Society for Gastroenterology and Hepatology (\u00d6GGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetix (ATX)","volume":"128","author":"4 Graziadei","year":"2016","unstructured":"4 Graziadei I, Zoller H, Fickert P, et al. Indications for liver transplantation in adults. Recommendations of the Austrian Society for Gastroenterology and Hepatology (\u00d6GGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetix (ATX). Wien Klin Wochenschr. 2016; 128: 679-690.","journal-title":"Wien Klin Wochenschr"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"5 Mazzaferro","year":"1996","unstructured":"5 Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med. 1996; 334: 693-699.","journal-title":"N Eng J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.ejso.2019.07.024","article-title":"Liver transplantation for unresectable malignancies: beyond hepatocellular carcinoma","volume":"45","author":"6 Amer","year":"2019","unstructured":"6 Amer A, Wilson CH, Manas DM. Liver transplantation for unresectable malignancies: beyond hepatocellular carcinoma. Eur J Surg Oncol. 2019; 45: 2268-2278.","journal-title":"Eur J Surg Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MOG.0b013e3283527f16","article-title":"Update in liver transplantation","volume":"28","author":"7 Alqahtani","year":"2012","unstructured":"7 Alqahtani SA. Update in liver transplantation. Curr Opin Gastroenterol. 2012; 28: 230-238.","journal-title":"Curr Opin Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0140-6736(99)90002-8","article-title":"Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage","volume":"354","author":"Neuberger J","year":"1999","unstructured":"8 Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet 1999; 354: 1636-1639.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jhep.2013.10.024","article-title":"Timing and benefit of liver transplantation in acute liver failure","volume":"60","author":"9 O'Grady","year":"2014","unstructured":"9 O'Grady J. Timing and benefit of liver transplantation in acute liver failure. J Hepatol. 2014; 60: 663-670.","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.3748\/wjg.v22.i10.2922","article-title":"Advances in liver transplantation allocation systems","volume":"22","author":"Schilsky ML","year":"2016","unstructured":"10 Schilsky ML, Moini M. Advances in liver transplantation allocation systems. World J Gastroenterol. 2016; 22: 2922-2930.","journal-title":"World J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/ctr.12420","article-title":"Developments in pediatric liver transplantation since implementation of the new allocation rules in Eurotransplant","volume":"28","author":"11 Herden","year":"2014","unstructured":"11 Herden U, Grabhorn E, Briem-Richter A, et al. Developments in pediatric liver transplantation since implementation of the new allocation rules in Eurotransplant. Clin Transplant. 2014; 28: 1061-1068.","journal-title":"Clin Transplant"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Carithers LR Jr. Liver transplantation. American Association for the Study of Liver Diseases practice guidelines. Liver Transpl. 2000; 6: 122-135.","DOI":"10.1002\/lt.500060122"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"13 D'Amico","year":"2006","unstructured":"13 D'Amico D, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44: 217-231.","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007; 47: 460-466.","DOI":"10.1016\/j.jhep.2007.07.004"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/lt.24805","article-title":"Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without Model for End-Stage Liver Disease exceptions","volume":"23","author":"15 Umgelter","year":"2017","unstructured":"15 Umgelter A, Hapfelmeier A, Kopp W, et al. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without Model for End-Stage Liver Disease exceptions. Liver Transpl. 2017; 23: 1256-1265.","journal-title":"Liver Transpl"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1097\/TP.0000000000001631","article-title":"Adult liver allocation in Eurotransplant","volume":"101","author":"16 Jochmans","year":"2017","unstructured":"16 Jochmans I, van Rosmalen M, Pirenne J, et al. Adult liver allocation in Eurotransplant. Transplantation 2017; 101: 1543-1550.","journal-title":"Transplantation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/TP.0000000000002355","article-title":"Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic or AIH cirrhosis","volume":"103","author":"17 Thuluwath","year":"2019","unstructured":"17 Thuluwath PJ, Hanish S, Savva Y. Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic or AIH cirrhosis. Transplantation 2019; 103: 113-121.","journal-title":"Transplantation"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jhep.2015.11.015","article-title":"Liver transplant center variability in accepting organ offers and its impact on patient survival","volume":"64","author":"18 Goldberg","year":"2016","unstructured":"18 Goldberg DS, French B, Lewis JD, et al. Liver transplant center variability in accepting organ offers and its impact on patient survival. J Hepatol. 2016; 64: 843-851.","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","article-title":"Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from the Nordic Liver Transplant Registry 1982-2013","volume":"50","author":"19 Fosby","year":"2015","unstructured":"19 Fosby B, Melum E, Bj\u00f8ro K, et al. Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from the Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol. 2015; 50: 797-808.","journal-title":"Scand J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Berenguer M, de la Rosa Rodr\u00edguez G, Dom\u00ednguez-Gil B. Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. Letters to the editor. J Hepatol. 2018; 69: 966-968.","DOI":"10.1016\/j.jhep.2018.06.011"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Kim WR, Lake JR, Smith JM, et al. OPTN\/SRTR 2017 annual data report: liver. Am J Transplant. 2019; 19(Suppl 2): 184-283.","DOI":"10.1111\/ajt.15276"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.transproceed.2016.01.058","article-title":"Liver donation and transplantation in Poland: numbers, indicators, and trends","volume":"48","author":"22 Czerwi\u0144ski","year":"2016","unstructured":"22 Czerwi\u0144ski J, Lewandowska D, Ma\u0142kowski P, et al. Liver donation and transplantation in Poland: numbers, indicators, and trends. Transplant Proc. 2016; 48: 1341-1346.","journal-title":"Transplant Proc"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/lt.24461","article-title":"Liver transplantation in Germany","volume":"22","author":"23 Tacke","year":"2016","unstructured":"23 Tacke F, Kroy DC, Barreiros AP, et al. Liver transplantation in Germany. Liver Transpl. 2016; 22: 1136-1142.","journal-title":"Liver Transpl"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 Johnson RJ, Bradbury LL, Martin K, et al. Organ donation and transplantation in the UK - the last decade: a report from the UK National Transplant Registry. Transplantation 2014; 97: S1-S27.","DOI":"10.1097\/01.TP.0000438215.16737.68"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/lt.25419","article-title":"Liver transplantation in France","volume":"25","author":"25 Durand","year":"2019","unstructured":"25 Durand F, Antoine C, Soubrane O. Liver transplantation in France. Liver Transpl. 2019; 25: 763-770.","journal-title":"Liver Transpl"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.transproceed.2018.02.021","article-title":"Stratifying mortality in a Model for End-Stage Liver Disease waiting list: a Brazilian single-center study","volume":"50","author":"26 Martino","year":"2018","unstructured":"26 Martino RB, Waisberg DR, Dias AP, et al. Stratifying mortality in a Model for End-Stage Liver Disease waiting list: a Brazilian single-center study. Transplant Proc. 2018; 50: 758-761.","journal-title":"Transplant Proc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.transproceed.2019.01.192","article-title":"Analysis of the liver transplantation waiting list in our center","volume":"51","author":"27 Emek","year":"2019","unstructured":"27 Emek E, Yesim Kara Z, Demircan FH, et al. Analysis of the liver transplantation waiting list in our center. Transplant Proc. 2019; 51: 2413-2415.","journal-title":"Transplant Proc"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.surg.2017.10.009","article-title":"Racial and regional disparity in liver transplant allocation","volume":"163","author":"28 Monlezun","year":"2018","unstructured":"28 Monlezun DJ, Darden M, Friedlander P, et al. Racial and regional disparity in liver transplant allocation. Surgery 2018; 163: 612-616.","journal-title":"Surgery"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.puhe.2015.01.024","article-title":"Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection","volume":"129","author":"29 Edeghere","year":"2015","unstructured":"29 Edeghere O, Verlander NQ, Aboulhab J, et al. Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection. Public Health 2015; 129: 509-516.","journal-title":"Public Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/lt.25361","article-title":"Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand","volume":"25","author":"30 Calzadilla-Bertot","year":"2019","unstructured":"30 Calzadilla-Bertot L, Jeffrey GP, Jacques B, et al. Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand. Liver Transpl. 2019; 25: 25-34.","journal-title":"Liver Transpl"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.13751","article-title":"Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries","volume":"38","author":"31 Holmer","year":"2018","unstructured":"31 Holmer M, Melum E, Isoniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int. 2018; 38: 2082-2090.","journal-title":"Liver Int"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32 Yang JD, Larson JJ, Watt KD, et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement in the waitlist in the United States. Clin Gastroenterol Hepatol. 2017; 15: 767-775.e3.","DOI":"10.1016\/j.cgh.2016.11.034"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33 de Boer JD, Braat AE, Putter H, et al. Outcome of liver tansplant patients with high urgent priority: are we doing the right thing? Transplantation 2019; 103: 1181-1190.","DOI":"10.1097\/TP.0000000000002526"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/liv.13523","article-title":"Weighing the risks: morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list","volume":"38","author":"34 Kardashian","year":"2018","unstructured":"34 Kardashian AA, Dodge JL, Roberts J, et al. Weighing the risks: morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int. 2018; 38: 553-563.","journal-title":"Liver Int"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"35 Pimpin","year":"2018","unstructured":"35 Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69: 718-735.","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/apt.15060","article-title":"Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades","volume":"49","author":"36 Harms","year":"2019","unstructured":"36 Harms MH, Janssen QP, Adam R, et al. Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther. 2019; 49: 285-295.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00535-013-0782-5","article-title":"Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system","volume":"49","author":"37 Genda","year":"2014","unstructured":"37 Genda T, Ichida T, Sakisaka S, et al. Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system. J Gastroenterol. 2014; 49: 324-331.","journal-title":"J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.3748\/wjg.v24.i26.2785","article-title":"Liver transplantation and alcoholic liver disease: history, controversies and considerations","volume":"24","author":"38 Marroni","year":"2018","unstructured":"38 Marroni CA, Fleck AM Jr, Fernandes SA, et al. Liver transplantation and alcoholic liver disease: history, controversies and considerations. World J Gastroenterol. 2018; 24: 2785-2805.","journal-title":"World J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/lt.24502","article-title":"Liver transplantation in Japan","volume":"22","author":"39 Soyama","year":"2016","unstructured":"39 Soyama A, Eguchi S, Egawa H. Liver transplantation in Japan. Liver Transpl. 2016; 22: 1401-1407.","journal-title":"Liver Transpl"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/jvh.13022","article-title":"Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy","volume":"26","author":"40 Vaziri","year":"2019","unstructured":"40 Vaziri A, Gimson A, Agarwal K, et al. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy. J Viral Hepatol. 2019; 26: 231-235.","journal-title":"J Viral Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41 Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver translantation. Gastroenterology 2017; 152: 1090-1099.e1.","DOI":"10.1053\/j.gastro.2017.01.003"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42 Belli LS, Perricone G, Adam R, et al. Impact of DAAs in liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018; 69: 810-817.","DOI":"10.1016\/j.jhep.2018.06.010"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43 Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly incsreasing indication for liver transplantation in the United States. Clin Gastroenterol and Hepatol. 2021; 19: 580-589.e5.","DOI":"10.1016\/j.cgh.2020.05.064"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.dld.2019.08.022","article-title":"Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma","volume":"52","author":"44 Singal","year":"2020","unstructured":"44 Singal AK, Satapathy SK, Reau N, et al. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liv Dis. 2020; 52: 98-101.","journal-title":"Dig Liv Dis"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45 Kwong A, Mehta N. Expanding the limits of liver transplantation for hepatocellular carcinoma: is there a limit? Clin Liver Dis. 2021; 25: 19-33.","DOI":"10.1016\/j.cld.2020.08.002"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/TP.0000000000003212","article-title":"Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS Transplant Oncology Consensus Conference","volume":"104","author":"46 Sapisochin","year":"2020","unstructured":"46 Sapisochin G, Javle M, Lerut J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1125-1130.","journal-title":"Transplantation"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1111\/j.1600-6143.2007.01961.x","article-title":"The challenging triangle: balancing outcomes, transplant numbers and costs","volume":"7","author":"47 Howard","year":"2007","unstructured":"47 Howard RJ. The challenging triangle: balancing outcomes, transplant numbers and costs. Am J Transplant. 2007; 7: 2443-2445.","journal-title":"Am J Transplant"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12916-018-1110-y","article-title":"Management of patients with liver diseases on the waiting list for transplantation: a major impact to the succes of liver transplantation","volume":"16","author":"Samuel D","year":"2018","unstructured":"48 Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the succes of liver transplantation. BMC Med. 2018; 16: 113.","journal-title":"BMC Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ajt.15144","article-title":"Transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change","volume":"19","author":"49 Ishaque","year":"2019","unstructured":"49 Ishaque T, Massie AB, Bowring MD, et al. Transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. Am J Transplant. 2019; 19: 564-572.","journal-title":"Am J Transplant"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/8\/article-p301.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/8\/article-p301.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/8\/article-p301.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:44:57Z","timestamp":1698227097000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/8\/article-p301.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":49,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32356","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}